QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • BrainStorm Cell Therapeutics, Inc. (BCLI) To Commence Multiple Sclerosis Study At Hadassah Medical Center 0 comments
    Oct 16, 2013 10:43 AM | about stocks: BCLI

    BrainStorm Cell Therapeutics, a biotech company engaged in the development adult stem cell technologies for neurodegenerative diseases, reports that it will initiate a pre-clinical study for multiple sclerosis (NYSE:MS) at the Hebrew University Hadassah Medical Center's SPF-grade animal laboratory in Jerusalem.

    Based on favorable pre-clinical data published by BrainStorm chief scientist Professor Daniel Offen of Tel Aviv University, the company says it will conduct additional studies using the Experimental Autoimmune Encephalomyelitis (EAE) animal model to evaluate MS as an additional indication for its NurOwn™ technology.

    NurOwn induces bone marrow-derived mesenchymal stem cells (NYSEARCA:MSC) to secrete high levels of neurotrophic factors to protect existing motor neurons, promotion of motor neuron growth, and re-establish nerve-muscle interaction.

    Professor Dimitrios Karussis and Dr. Ibrahim Kassis, who have published extensively on pre-clinical research using the EAE model, will be the principal investigators of BrainStorm's upcoming study.

    The study was approved by the Institutional Animal Care and Use Committee (IACUC) of the Hebrew University.

    Professor Karussis, a key opinion leader in the field of MS, is head of the multi-disciplinary MS Clinic and Center at Hadassah, member of the European Steering Committee for Bone Marrow Transplantation in MS, and a member of the Executive Board and Scientific Committee of the European School of Neuroimmunology (ESNI). He is also former board member of the European Council and Committee for Treatment and Research in MS, and has been the principal investigator of several multi-national clinical trials in MS conducted by global pharmaceutical companies.

    For more information, visit brainstorm-cell.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: BCLI
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.